vs
Asana, Inc.（ASAN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Asana, Inc.的季度营收约是再鼎医药的1.6倍（$201.0M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.3%），Asana, Inc.自由现金流更多（$15.5M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 8.4%）
Asana是一家总部位于美国旧金山的软件企业，由达斯汀·莫斯科维茨和贾斯汀·罗森斯坦于2008年创立，核心产品是同名工作管理平台，支持网页端与移动端使用，可帮助团队梳理、跟踪及统筹各类工作事项，2012年4月正式商业化推出，2020年9月直接上市，当时估值达55亿美元。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ASAN vs ZLAB — 直观对比
营收规模更大
ASAN
是对方的1.6倍
$127.1M
营收增速更快
ZLAB
高出7.8%
9.3%
自由现金流更多
ASAN
多$42.2M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
8.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $201.0M | $127.1M |
| 净利润 | $-68.4M | — |
| 毛利率 | 88.9% | 51.0% |
| 营业利润率 | -34.8% | -54.6% |
| 净利率 | -34.0% | — |
| 营收同比 | 9.3% | 17.1% |
| 净利润同比 | -19.4% | — |
| 每股收益（稀释后） | $-0.29 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASANZLAB
| Q4 25 | $201.0M | $127.1M | ||
| Q3 25 | $196.9M | $115.4M | ||
| Q2 25 | $187.3M | $109.1M | ||
| Q1 25 | $188.3M | $105.7M | ||
| Q4 24 | $183.9M | $108.5M | ||
| Q3 24 | $179.2M | $101.8M | ||
| Q2 24 | $172.4M | $100.1M | ||
| Q1 24 | $171.1M | $87.1M |
净利润ASANZLAB
| Q4 25 | $-68.4M | — | ||
| Q3 25 | $-48.4M | $-36.0M | ||
| Q2 25 | $-40.0M | $-40.7M | ||
| Q1 25 | $-62.3M | $-48.4M | ||
| Q4 24 | $-57.3M | — | ||
| Q3 24 | $-72.2M | $-41.7M | ||
| Q2 24 | $-63.7M | $-80.3M | ||
| Q1 24 | $-62.4M | $-53.5M |
毛利率ASANZLAB
| Q4 25 | 88.9% | 51.0% | ||
| Q3 25 | 89.7% | 59.5% | ||
| Q2 25 | 89.7% | 60.6% | ||
| Q1 25 | 89.6% | 63.6% | ||
| Q4 24 | 89.2% | 61.5% | ||
| Q3 24 | 88.8% | 64.1% | ||
| Q2 24 | 89.7% | 64.9% | ||
| Q1 24 | 89.8% | 61.4% |
营业利润率ASANZLAB
| Q4 25 | -34.8% | -54.6% | ||
| Q3 25 | -25.1% | -42.3% | ||
| Q2 25 | -23.4% | -50.3% | ||
| Q1 25 | -33.8% | -53.3% | ||
| Q4 24 | -32.7% | -62.6% | ||
| Q3 24 | -42.9% | -66.6% | ||
| Q2 24 | -38.4% | -76.0% | ||
| Q1 24 | -39.7% | -80.7% |
净利率ASANZLAB
| Q4 25 | -34.0% | — | ||
| Q3 25 | -24.6% | -31.2% | ||
| Q2 25 | -21.4% | -37.3% | ||
| Q1 25 | -33.1% | -45.8% | ||
| Q4 24 | -31.2% | — | ||
| Q3 24 | -40.3% | -40.9% | ||
| Q2 24 | -37.0% | -80.2% | ||
| Q1 24 | -36.5% | -61.4% |
每股收益（稀释后）ASANZLAB
| Q4 25 | $-0.29 | $-0.05 | ||
| Q3 25 | $-0.20 | $-0.03 | ||
| Q2 25 | $-0.17 | $-0.04 | ||
| Q1 25 | $-0.27 | $-0.04 | ||
| Q4 24 | $-0.25 | $-0.09 | ||
| Q3 24 | $-0.31 | $-0.04 | ||
| Q2 24 | $-0.28 | $-0.08 | ||
| Q1 24 | $-0.28 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $183.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $188.4M | $715.5M |
| 总资产 | $840.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASANZLAB
| Q4 25 | $183.5M | $689.6M | ||
| Q3 25 | $184.1M | $717.2M | ||
| Q2 25 | $193.8M | $732.2M | ||
| Q1 25 | $184.7M | $757.3M | ||
| Q4 24 | $196.8M | $779.7M | ||
| Q3 24 | $219.4M | $616.1M | ||
| Q2 24 | $222.0M | $630.0M | ||
| Q1 24 | $236.7M | $650.8M |
股东权益ASANZLAB
| Q4 25 | $188.4M | $715.5M | ||
| Q3 25 | $224.6M | $759.9M | ||
| Q2 25 | $236.3M | $791.7M | ||
| Q1 25 | $227.5M | $810.8M | ||
| Q4 24 | $239.3M | $840.9M | ||
| Q3 24 | $291.9M | $667.7M | ||
| Q2 24 | $319.9M | $704.2M | ||
| Q1 24 | $326.4M | $762.2M |
总资产ASANZLAB
| Q4 25 | $840.4M | $1.2B | ||
| Q3 25 | $883.2M | $1.2B | ||
| Q2 25 | $877.1M | $1.2B | ||
| Q1 25 | $891.4M | $1.2B | ||
| Q4 24 | $874.2M | $1.2B | ||
| Q3 24 | $945.4M | $985.3M | ||
| Q2 24 | $978.2M | $987.4M | ||
| Q1 24 | $962.0M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $15.5M | $-26.7M |
| 自由现金流率自由现金流/营收 | 7.7% | -21.0% |
| 资本支出强度资本支出/营收 | 0.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $74.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ASANZLAB
| Q4 25 | $16.2M | $-26.0M | ||
| Q3 25 | $39.8M | $-32.0M | ||
| Q2 25 | $6.8M | $-31.0M | ||
| Q1 25 | $15.9M | $-61.7M | ||
| Q4 24 | $-14.9M | $-55.8M | ||
| Q3 24 | $15.9M | $-26.8M | ||
| Q2 24 | $-1.9M | $-42.2M | ||
| Q1 24 | $-15.3M | $-90.1M |
自由现金流ASANZLAB
| Q4 25 | $15.5M | $-26.7M | ||
| Q3 25 | $38.5M | $-35.0M | ||
| Q2 25 | $6.1M | $-33.9M | ||
| Q1 25 | $14.3M | $-63.2M | ||
| Q4 24 | $-16.3M | $-58.4M | ||
| Q3 24 | $14.2M | $-28.2M | ||
| Q2 24 | $-2.9M | $-42.9M | ||
| Q1 24 | $-15.8M | $-91.1M |
自由现金流率ASANZLAB
| Q4 25 | 7.7% | -21.0% | ||
| Q3 25 | 19.6% | -30.4% | ||
| Q2 25 | 3.3% | -31.1% | ||
| Q1 25 | 7.6% | -59.9% | ||
| Q4 24 | -8.8% | -53.8% | ||
| Q3 24 | 7.9% | -27.7% | ||
| Q2 24 | -1.7% | -42.9% | ||
| Q1 24 | -9.3% | -104.5% |
资本支出强度ASANZLAB
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.8% | 1.5% | ||
| Q4 24 | 0.7% | 2.4% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 0.6% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASAN
| US | $118.5M | 59% |
| Non Us | $82.5M | 41% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
